Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments.

In an era in which it is possible to deliver radiation with high precision, there is a heightened need for enhanced imaging capabilities to improve tumour localisation for diagnostic, planning and delivery purposes. This is necessary to increase the accuracy and overall efficacy of all types of external beam radiotherapy (RT), including particle therapies. Positron emission tomography (PET) has the potential to fulfil this need by imaging fundamental aspects of tumour biology. The key areas in which PET may support the RT process include improving disease diagnosis and staging; assisting tumour volume delineation; defining tumour phenotype or biological tumour volume; assessment of treatment response; and in-beam monitoring of radiation dosimetry. The role of PET and its current developmental status in these key areas are overviewed in this review, highlighting the advantages and drawbacks.

[1]  Thomas Beyer,et al.  Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Anne Bol,et al.  The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Yoshimi Anzai,et al.  FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[5]  P. Price,et al.  The Role of PET in Target Localization for Radiotherapy Treatment Planning , 2008, Oncology Research and Treatment.

[6]  K Schnabel,et al.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.

[7]  Randall K Ten Haken,et al.  Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. , 2009, International journal of radiation oncology, biology, physics.

[8]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[9]  Julie R. Gralow,et al.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Enghardt,et al.  In-beam PET at high-energy photon beams: a feasibility study , 2006, Physics in medicine and biology.

[11]  J. Mortensen,et al.  The Future in Diagnosis and Staging of Lung Cancer: Positron Emission Tomography , 2006, Respiration.

[12]  Branislav Jeremic,et al.  L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[13]  Pedro Andreo,et al.  On the clinical spatial resolution achievable with protons and heavier charged particle radiotherapy beams , 2009, Physics in medicine and biology.

[14]  Terry Jones,et al.  The role of positron emission tomography within the spectrum of medical imaging , 1996, European Journal of Nuclear Medicine.

[15]  H. Bartelink,et al.  In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. , 2004, International journal of radiation oncology, biology, physics.

[16]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[17]  Anders Brahme,et al.  Recent advances in light ion radiation therapy. , 2004, International Journal of Radiation Oncology, Biology, Physics.

[18]  Dean Billheimer,et al.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Philippe Lambin,et al.  The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. , 2006, Cancer treatment reviews.

[20]  P. Bossuyt,et al.  Limited additional value of positron emission tomography in staging oesophageal cancer , 2007, The British journal of surgery.

[21]  Jean-François Daisne,et al.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.

[22]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Keiichi Nakagawa,et al.  The development and clinical use of a beam ON-LINE PET system mounted on a rotating gantry port in proton therapy. , 2008, International journal of radiation oncology, biology, physics.

[24]  S. Kalnicki,et al.  Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume. , 2008, Seminars in nuclear medicine.

[25]  Jeffrey D Bradley,et al.  Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  M. Graham,et al.  Comparison of simplified quantitative analyses of FDG uptake. , 2000, Nuclear medicine and biology.

[27]  K Parodi,et al.  In-beam PET measurement of 7Li3+ irradiation induced beta+-activity. , 2008, Physics in medicine and biology.

[28]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[29]  S. Webb,et al.  Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  Curtis B Caldwell,et al.  Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. , 2003, International journal of radiation oncology, biology, physics.

[31]  Tove Grönroos,et al.  Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. , 2004, International Journal of Radiation Oncology, Biology, Physics.

[32]  S. Reske,et al.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[34]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[35]  Pek-Lan Khong,et al.  Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. , 2009, Radiology.

[36]  J. Plukker,et al.  Role of positron emission tomography in the (re-)staging of oesophageal cancer , 2006, Scandinavian journal of gastroenterology. Supplement.

[37]  P. Lambin,et al.  Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients , 2007 .

[38]  Johannes A Langendijk,et al.  Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  Jinming Yu,et al.  Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. , 2009, International journal of radiation oncology, biology, physics.

[40]  J. Buatti,et al.  Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. , 2009, International journal of radiation oncology, biology, physics.

[41]  Katia Parodi,et al.  In-beam PET measurements of β+ radioactivity induced by proton beams , 2002 .

[42]  F MURRAY,et al.  Diagnosis and treatment of lung cancer. , 1955, Geriatrics.

[43]  John L. Humm,et al.  Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  Thomas Beyer,et al.  Dual-modality PET/CT instrumentation-today and tomorrow. , 2010, European journal of radiology.

[45]  Morand Piert,et al.  Experience of PET for target localisation in radiation oncology , 2005 .

[46]  F. Grünwald,et al.  Die Positronenemissionstomographie zur präoperativen Lymphknotendiagnostik bei Ösophaguskarzinom , 2003, Der Chirurg.

[47]  J. Buatti,et al.  The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. , 2005, International journal of radiation oncology, biology, physics.

[48]  Dag Rune Olsen,et al.  Strategies for biologic image-guided dose escalation: a review. , 2009, International journal of radiation oncology, biology, physics.

[49]  N Cascinelli,et al.  Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  H. Minn,et al.  Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  R Jeraj,et al.  Comparison of intensity modulated x-ray therapy and intensity modulated proton therapy for selective subvolume boosting: a phantom study , 2007, Physics in medicine and biology.

[52]  D. Visvikis,et al.  The role of PET/CT scanning in radiotherapy planning. , 2006, The British journal of radiology.

[53]  N. Moriyama,et al.  Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional X-ray plans in patients with pediatric cancers , 2010, Annals of nuclear medicine.

[54]  Gig Mageras,et al.  Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[55]  Ellen Yorke,et al.  18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy* , 2009, Journal of Nuclear Medicine.

[56]  Norbert Avril,et al.  Relevance of Positron Emission Tomography (PET) in Oncology , 1999, Strahlentherapie und Onkologie.

[57]  Ursula Nestle,et al.  Biological imaging in radiation therapy: role of positron emission tomography , 2009, Physics in medicine and biology.

[58]  S. Nehmeh,et al.  Respiratory motion in positron emission tomography/computed tomography: a review. , 2008, Seminars in nuclear medicine.

[59]  K Parodi,et al.  In-beam PET monitoring of mono-energetic 16O and 12C beams: experiments and FLUKA simulations for homogeneous targets , 2009, Physics in medicine and biology.

[60]  Aswin L Hoffmann,et al.  Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer? , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[61]  Branislav Jeremic,et al.  Positron Emission Tomography for Radiation Treatment Planning , 2005, Strahlentherapie und Onkologie.

[62]  Alfred A Bartolucci,et al.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.

[63]  T. Jones The imaging science of positron emission tomography , 1996, European Journal of Nuclear Medicine.

[64]  P. Choyke,et al.  Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. , 2010, Discovery medicine.

[65]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[66]  P. Price,et al.  Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue , 2009, Molecular Cancer Therapeutics.

[67]  A. Riegel,et al.  Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. , 2005, International journal of radiation oncology, biology, physics.

[68]  Tomio Inoue,et al.  Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  David Binns,et al.  Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. , 2004, International journal of radiation oncology, biology, physics.

[70]  S Leide-Svegborn,et al.  Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. , 2010, Radiation protection dosimetry.

[71]  J. Plukker,et al.  Staging in oesophageal cancer. , 2006, Best practice & research. Clinical gastroenterology.

[72]  E Yorke,et al.  Four-dimensional (4D) PET/CT imaging of the thorax. , 2004, Medical physics.

[73]  L. Kong,et al.  [Correlation between PET-CT 18FDG uptake in primary lesions and clinicopathological parameters in esophageal carcinoma patients]. , 2009, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[74]  Aswin L Hoffmann,et al.  Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[75]  Karin Haustermans,et al.  Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[76]  P. Jarritt,et al.  Personnel radiation dose considerations in the use of an integrated PET-CT scanner for radiotherapy treatment planning. , 2009, The British journal of radiology.

[77]  Yoshimi Anzai,et al.  FDG‐PET/CT–guided intensity modulated head and neck radiotherapy: A pilot investigation , 2005, Head & neck.

[78]  Rita Engenhart-Cabillic,et al.  Ion beam radiobiology and cancer: time to update ourselves. , 2009, Biochimica et biophysica acta.

[79]  Wim J. G. Oyen,et al.  Methodological considerations in quantification of oncological FDG PET studies , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[80]  Johan Bussink,et al.  Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET , 2010, Journal of Nuclear Medicine.

[81]  Katia Parodi,et al.  In-beam PET measurements of biological half-lives of 12C irradiation induced β+-activity , 2008, Acta oncologica.